Fig 1.
Patient inclusion criteria and subgroups for cross-sectional analysis of bone markers, influence of rhGH treatment and predictors of height and growth.
Table 1.
Subject characteristics.
Fig 2.
Distribution of serum bone marker concentrations in 510 pediatric CKD patients. Data are expressed as standard deviation scores (SDS).
The shaded area depicts the normal range (5th to 95th percentile of biomarker concentrations in healthy children)[8]. Asterisks indicate significant deviation from distribution in the reference population (*: p<0.05, **: p<0.0001 compared to healthy controls).
Table 2.
Distribution of serum bone markers by CKD stage.
Table 3.
Predictors of standardized bone marker concentrations; results of stepwise multiple linear regression analyses.
Table 4.
Predictors of baseline and prospective change in standardized height in total cohort; results of stepwise multiple linear regression analyses.
Table 5.
Subject Characteristics for groups matched for GH treatment.
Fig 3.
Distribution of serum bone marker concentrations in children with and without rhGH treatment (n = 41 per group).
Data are expressed as standard deviation scores (SDS). The shaded area depicts the normal range (5th to 95th percentile of biomarker concentrations in healthy children)8. Asterisks indicate significant deviation from distribution in the reference population (*: p<0.05, **: p<0.01).
Table 6.
Bone markers in groups matched for GH treatment.